Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Status:
RECRUITING
Trial end date:
2027-03-14
Target enrollment:
Participant gender:
Summary
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.